Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase Ib/II Trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With Toripalimab in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

NCT05103917 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT05103917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase Ib/II Trial to Study the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With Toripalimab in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 21, 2021
Completion date
May 21, 2023
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer